|
|
Volumn 102, Issue 3, 2010, Pages 144-146
|
|
Researchers consider value-of-information theory for selecting trials.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ARTICLE;
CLINICAL TRIAL;
DECISION MAKING;
ECONOMICS;
HUMAN;
INFORMATION SCIENCE;
NEOPLASM;
QUALITY ADJUSTED LIFE YEAR;
RARE DISEASE;
STANDARD;
UNCERTAINTY;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DECISION MAKING;
HUMANS;
INFORMATION THEORY;
NEOPLASMS;
QUALITY-ADJUSTED LIFE YEARS;
RARE DISEASES;
UNCERTAINTY;
|
|
EID: 77449152565
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq015 Document Type: Article |
|
Times cited : (10)
|
|
References (0)
|
